4.8 Letter

Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Editorial Material Medicine, General & Internal

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2021)

Review Public, Environmental & Occupational Health

The Danish health care system and epidemiological research: from health care contacts to database records

Morten Schmidt et al.

CLINICAL EPIDEMIOLOGY (2019)

Review Public, Environmental & Occupational Health

The Danish National Patient Registry: a review of content, data quality, and research potential

Morten Schmidt et al.

CLINICAL EPIDEMIOLOGY (2015)

Article Medicine, General & Internal

Secular Trends in Occurrence of Acute Venous Thromboembolism: The Worcester VTE Study (1985-2009)

Wei Huang et al.

AMERICAN JOURNAL OF MEDICINE (2014)

Article Medicine, General & Internal

Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort

Vicky Tagalakis et al.

AMERICAN JOURNAL OF MEDICINE (2013)

Article Hematology

Incidence and mortality of venous thrombosis:: a population-based study

I. A. Naess et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)